[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Pandemic Science, Reinfections and hydroxychloroquine", "description": "2 European reinfections\n\nhttps://www.independent.co.uk/news/health/coronavirus-reinfection-netherlands-belgium-hong-kong-covid-19-update-a9687301.html\n\nNetherlands \n\nMarion Koopmans (virologist)\n\nViral genomes were different\n\nOlder person with a weakened immune system\n\nReinfections had been expected.\n\nWe have to see whether it happens often\n\nBelgium\n\nWoman, first time in March, second time in June\n\nMarc Van Ranst (virologist)\n\nWoman\u2019s symptoms relatively mild\n\nMay not have created enough antibodies to prevent a reinfection\n\nThey might have helped limit the sickness\n\nI think that in the coming days that we will see other similar stories\n\nIt\u2019s not good news\n\nHow common\n\nHigh levels of surveillance\n\nUse of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study (European Journal of Internal Medicine,\n\nImmunomodulatory\n\nAnti-inflammatory\n\nAnti-thrombotic\n\nDirectly inhibits viral entry and spread in several in vitro and in vivo models \n\nMight inhibit ACE 2, reduced internalization of the virus \n\nhttps://www.ejinme.com/article/S0953-6205(20)30335-6/fulltext \n\nhttps://www.ejinme.com/action/showPdf?pii=S0953-6205%2820%2930335-6\n\nMulticenter Italian collaboration, relationship between HCQ therapy and COVID-19 in-hospital mortality\n\nMethods\n\nRetrospective observational study\n\nN = 3,451\n\n33 clinical centers in Italy\n\nFebruary 19th to May 23rd \n\nLaboratory-confirmed SARS-CoV-2 infection\n\nComparing patients who received HCQ with patients who did not\n\nDose\n\nHCQ, all centres, 400 mg/day \n\nOne centre, 600 mg/day\n\n5 to 15 days\n\nDose, BNF link\n\nhttps://bnf.nice.org.uk/drug/hydroxychloroquine-sulfate.html\n\nResults\n\nOut of 3,451\n\n76.3% received HCQ\n\nHCQ group\n\nN  = 2633\n\nDeath rate 8.9\n\nPer, 1,000 person days\n\nNon HCQ group\n\nN = 817\n\nDeath rate 15.7\n\nAfter adjustment for propensity scores\n\n30% lower risk of death in patients receiving HCQ\n\nHR=0.70;\n\n95%CI: 0.59 to 0.84;\n\nHCQ use was associated with a 30% reduced death rate\n\n95%CI: 16% to 41%\n\nThese data do not discourage the use of HCQ in inpatients with COVID-19\n\nEffect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis (26 August, Clinical Microbiology and Infection, France)\n\nhttps://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30505-X/fulltext\n\nhttps://www.clinicalmicrobiologyandinfection.com/action/showPdf?pii=S1198-743X%2820%2930505-X\n\n839 articles\n\n29 articles met our inclusion criteria\n\nIncluding 3 RCTs\n\nEvaluated the effects of hydroxychloroquine with or without azithromycin (except one)\n\nMeta-analysis \n\nHydroxychloroquine group\n\nn = 11,932 participants for the,\n\nAssociation with mortality\n\nRR = 0.83 (not significant)\n\nHydroxychloroquine with azithromycin group\n\nN = 8081\n\nRR = 1.27\n\nIncreased risk or mortality\n\nWe identified a significant absolute risk difference of +7%\n\nControl group\n\nN = 12,930\n\nConclusion\n\nHydroxychloroquine alone was not associated with reduced mortality in hospitalized COVID-19 patients\n\nthe combination of hydroxychloroquine and azithromycin significantly increased mortality\n\n\nWHO, Solidarity clinical trial for COVID-19 treatments\n\nhttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments\n\nOn 4 July 2020, WHO accepted the recommendation from the Solidarity Trial\u2019s International Steering Committee to discontinue the trial\u2019s hydroxychloroquine and lopinavir/ritonavir arms.\n\nWHO dose in Solidarity trial\n\nhttps://www.palmerfoundation.com.au/who-solidarity-and-uk-recovery-clinical-trials-of-hydroxychloroquine-using-potentially-fatal-doses/\n\nCanadian arm\n\nhttps://clinicaltrials.gov/ct2/show/NCT04330690\n\nTreatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)\n\nHydroxychloroquine 800mg BID for 1 day\n\nthen 400mg BID for 10 days plus optimized supportive care,\n\nLancet, retracted paper\n\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext#%20\n\nWe were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide\n\n\nRisk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study (lancet 21st august\n\nhttps://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30276-9/fulltext\n\nRetrospective, multinational, cohort\n\nN = 956 374 \n\nHydroxychloroquine treatment appears to have no increased risk in the short term among patients with rheumatoid arthritis\n\nLong term it appears to be associated with excess cardiovascular mortality\n\nThe addition of azithromycin increases the risk of heart failure and cardiovascular mortality \neven in the short term. \n\nWe call for careful consideration of the benefit\u2013risk trade-off when counselling those on hydroxychloroquine treatment.", "link": "https://www.youtube.com/watch?v=SBn4e69tGlg", "date_published": "2020-08-28 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Pandemic update from Iraq", "description": "Professor Raghad Alsuhail from Iraq bring us up to date with developments in her country. Raghad is Professor of virology and immunology at the University of Baghdad.", "link": "https://www.youtube.com/watch?v=J2pt7owNsBU", "date_published": "2020-08-28 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Hydroxychloroquine, evidence of efficacy", "description": "Belgium, not Dutch. Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants (International Journal of Antimicrobial Agents, 24 August)\n\nhttps://www.sciencedirect.com/science/article/pii/S0924857920303423\n\nBackground\n\nHydroxychloroquine (HCQ) has been largely used and investigated as therapy of COVID-19 , at total dose usually ranging from 2400 mg to 9600 mg.\n\nIn Belgium, off-label use of low-dose HCQ (2400 mg in total over five days) was recommended for hospitalized patients with COVID-19.\n\n\u201clow-dose\u201d regimen of HCQ sulphate in monotherapy \n\n400mg twice on day 1\n\n200mg twice a day from day 2 to 5\n\ni.e. a total dose of 2400 mg\n\nMethods\n\nMulti-centric design \n\nVast majority of Belgian hospitals\n\nRetrospective analysis\n\nIn-hospital mortality in Belgium\n\n40 day follow up\n\nNo difference in the baseline characteristics\n\nGroups\n\nHCQ alone and supportive care\n\nSupportive care only\n\nAdjusted for demographic and clinical features\n\nResults\n\n8075 patients with complete discharge data\n\nHCQ group, n = 4,542\n\nDeaths, 804, (17.7%)\n\nno-HCQ group, n = 3,533\n\nDeaths, 957 (27.1%)\n\nMultivariable analysis\n\nMortality was lower in the HCQ group compared to the no-HCQ group \n\nHazard ratio = 0.684\n\nEstimated direct-adjusted mortality at 40 days \n\n19.1% with HCQ alone\n\n26.5% with supportive care only\n\nMortality in the HCQ group was reduced\n\nBoth in patients diagnosed in less than 5 days and more than 5 days\n\nConclusions\n\nCompared to supportive care only, low-dose HCQ monotherapy was independently associated with lower mortality in hospitalized patients with COVID-19 diagnosed and treated early or later after symptom onset.\n\nOther positive studies\n\nhttps://www.sciencedirect.com/science/article/pii/S1477893920302817?via%3Dihub\n\nRisk Factors for Mortality in Patients with COVID-19 in New York City\n\nhttps://link.springer.com/article/10.1007/s11606-020-05983-z\n\nHydroxychloroquine use was associated with decreased in-hospital mortality\n\nTreatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 \n\nhttps://www.ijidonline.com/article/S1201-9712(20)30534-8/fulltext\n\ntreatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality\n\n\nRecovery Trial\n\nEffect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. 15 July 2020\n\nhttps://www.recoverytrial.net/results/hydroxychloroquine-results\n\nhttps://www.medrxiv.org/content/10.1101/2020.07.15.20151852v1.full.pdf\n\nHydroxychloroquine group, n = 1,561\n\nUsual care group, n = 3,155 \n\nPatients allocated to hydroxychloroquine sulfate (200mg) received a loading dose of 4 tablets (800 mg) at zero and 6 hours, followed by 2 tablets (400 mg) starting at 12 hours after the initial dose and then every 12 hours for the next 9 days\n\n9,200 mg over 10 days\n\nConclusion\n\nIn patients hospitalized with COVID-19, hydroxychloroquine was not associated with reductions in 28-day mortality\n\nWas associated with an increased length of hospital stay and increased risk of progressing to invasive mechanical ventilation or death \n\nWHO-led SOLIDARITY\n\nhttps://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19\n\n9600 mg over 10 days\n\nProvided no benefit in hospitalized patients with COVID-19\n\nHydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 (NEJM23 July) Brazil\n\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa2019014?query=C19&cid=DM95777_NEJM_Registered_Users_and_InActive&bid=234281688\n\nMETHODS\n\n55 hospitals, Brazil\n\nRandomized\n\nOpen label\n\nThree-group\n\nControlled\n\nPatients\n\n667 patients, 504 confirmed Covid-19\n\nReceiving no supplemental oxygen\n\nOr a maximum of 4 liters per minute \n\n1:1:1\n\nStandard care n = 229\n\nStandard care plus hydroxychloroquine (400 mg twice daily) n = 221\n\nStandard care plus hydroxychloroquine (400 mg twice daily) plus azithromycin (500 mg once \ndaily for 7 days) n = 277\n\nRESULTS\n\nNo difference in need for ventilation, deaths, thromboembolic complications, AKI\n\nClinical status at 15 days\n\nAs compared with standard care = 1\n\nHydroxychloroquine alone, odds ratio, 1.21\n\nHydroxychloroquine plus azithromycin, odds ratio, 0.99\n\nHCQ Group\n\nProlongation of the corrected QT interval and \n\nElevation of liver-enzyme levels\n\nCONCLUSIONS\nAmong patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care.", "link": "https://www.youtube.com/watch?v=2uzXHnUViro", "date_published": "2020-08-27 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]